AstraZeneca investors balk at reported $400bn Bristol Myers tie-up as analysts call deal 'perplexing'

New York Post — Business—Investors have pushed back against reports that AstraZeneca is in talks to acquire Bristol Myers Squibb in a deal valued near $400 billion, sending AstraZeneca shares lower as Wall Street analysts describe the rumored megadeal as 'perplexing.' One report has pegged the transaction's value as high as $512 billion, a discrepancy that underscores how early and unconfirmed the talks remain. If completed, the tie-up would rank among the largest pharmaceutical mergers ever, combining AstraZeneca's oncology pipeline with Bristol Myers' cancer-drug portfolio. Neither company has publicly confirmed the talks, and no timeline for a formal announcement has emerged.

• New York Post — Business — AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report
• Guardian — AstraZeneca holds talks with US cancer drug developer in $400bn merger
• The Straits Times — Pharma giants AstraZeneca, Bristol Myers Squibb in talks on $512 billion mega deal: Report
• CNBC — AstraZeneca slides after reports of Bristol Myers merger talks leave analysts 'perplexed'
• Financial Times — AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up
• Reuters — AstraZeneca held talks with Bristol Myers Squibb on $400 billion megadeal, source says
• Reuters — AstraZeneca investors balk at $400 billion Bristol Myers tie-up reports